Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.1
4.9
Journals
IJMS
Special Issues
Nanomedicine Advances in the Treatment of Chronic Inflammation
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Nanomedicine Advances in the Treatment of Chronic Inflammation

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Nanoscience".

Deadline for manuscript submissions: 20 May 2025 | Viewed by 3151

Special Issue Editors

Dr. Helena Ferreira

E-Mail Website
Guest Editor
3B’s Research Group, I3Bs-Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Barco, Portugal
Interests: nanomedicine; inflammatory diseases; cancer; biomaterials; nanotechnology; materials engineering and chemistry; advanced therapies; tissue engineering; regenerative medicine
Special Issues, Collections and Topics in MDPI journals
Dr. Nuno M. Neves

E-Mail Website
Guest Editor
I3B's-Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Guimarães, Portugal
Interests: biodegradable biomaterials; polymer science; natural origin biomaterials; surface biofunctionalization of biomaterials; innovative therapies for chronic inflammation; nanostructured biomaterials and composites; bone and cartilage tissue engineering; adult stem cells; advanced therapies; regenerative medicine; animal models for testing of biomaterials
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Rui L. Reis

E-Mail Website
Guest Editor
1. 3B’s Research Group, I3Bs—Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, Parque de Ciência e Tecnologia, Zona Industrial da Gandra, Barco, 4805-017 Guimarães, Portugal
2. ICVS/3B’s–PT Government Associate Laboratory, Braga, 4805-017 Guimarães, Portugal
Interests: tissue engineering; regenerative medicine; biomaterials; biomimetics; biodegradable materials; 3D in vitro models; cancer modelling
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Acute inflammation is an efficient and essential temporarily restricted response for the maintenance of human health. However, failure to resolve acute inflammation leads to serious pathological conditions that jointly represent the leading cause of death worldwide today. Indeed, numerous challenging and devastating diseases are mainly caused by chronic inflammation or include chronic inflammation as a pathophysiologically important component.

Despite remarkable improvements in recent decades in the treatment of inflammation-related diseases, three main drawbacks remain unresolved: (i) severe adverse effects that often create a very high risk/benefit ratio; (ii) the underexplored heterogeneity of disease mechanisms and among patients; and (iii) limited efficacy as patients present reduced life expectancy that may be worsened due to different comorbidities. Indeed, the presence of one inflammatory disorder increases the probability of developing other diseases. Thus, therapies that could safely and effectively treat chronic inflammation, overcoming these limitations, must urgently be developed.

This Special Issue aims to improve our knowledge about the latest achievements in chronic inflammation treatment. This Special Issue will publish original research articles regarding innovative, targeted, and/or precision nanomedicine strategies for chronic inflammation. Review articles with critical and detailed analysis of the published research and forecasting future avenues for research in this field are also valuable to this Special Issue.

Dr. Helena Ferreira
Dr. Nuno M. Neves
Prof. Dr. Rui L. Reis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

24 pages, 5838 KiB  
Article
Empowering Naringin’s Anti-Inflammatory Effects through Nanoencapsulation
by Andreia Marinho, Catarina Leal Seabra, Sofia A. C. Lima, Alexandre Lobo-da-Cunha, Salette Reis and Cláudia Nunes
Int. J. Mol. Sci. 2024, 25(8), 4152; https://doi.org/10.3390/ijms25084152 - 9 Apr 2024
Viewed by 1233
Abstract
Abundant in citrus fruits, naringin (NAR) is a flavonoid that has a wide spectrum of beneficial health effects, including its anti-inflammatory activity. However, its use in the clinic is limited due to extensive phase I and II first-pass metabolism, which limits its bioavailability. [...] Read more.
Abundant in citrus fruits, naringin (NAR) is a flavonoid that has a wide spectrum of beneficial health effects, including its anti-inflammatory activity. However, its use in the clinic is limited due to extensive phase I and II first-pass metabolism, which limits its bioavailability. Thus, lipid nanoparticles (LNPs) were used to protect and concentrate NAR in inflamed issues, to enhance its anti-inflammatory effects. To target LNPs to the CD44 receptor, overexpressed in activated macrophages, functionalization with hyaluronic acid (HA) was performed. The formulation with NAR and HA on the surface (NAR@NPsHA) has a size below 200 nm, a polydispersity around 0.245, a loading capacity of nearly 10%, and a zeta potential of about 10 mV. In vitro studies show the controlled release of NAR along the gastrointestinal tract, high cytocompatibility (L929 and THP-1 cell lines), and low hemolytic activity. It was also shown that the developed LNPs can regulate inflammatory mediators. In fact, NAR@NPsHA were able to decrease TNF-α and CCL-3 markers expression by 80 and 90% and manage to inhibit the effects of LPS by around 66% for IL-1β and around 45% for IL-6. Overall, the developed LNPs may represent an efficient drug delivery system with an enhanced anti-inflammatory effect. Full article
(This article belongs to the Special Issue Nanomedicine Advances in the Treatment of Chronic Inflammation)
►▼ Show Figures

Figure 1

19 pages, 45104 KiB  
Article
Synergistic Effect of Nilavembu Choornam–Gold Nanoparticles on Antibiotic-Resistant Bacterial Susceptibility and Contact Lens Contamination-Associated Infectious Pathogenicity
by Essam S. Almutleb, Samivel Ramachandran, Adnan A. Khan, Gamal A. El-Hiti and Saud A. Alanazi
Int. J. Mol. Sci. 2024, 25(4), 2115; https://doi.org/10.3390/ijms25042115 - 9 Feb 2024
Viewed by 1417
Abstract
Antibiotic-resistant bacterial colonies mitigate rapid biofilm formation and have complex cell wall fabrications, making it challenging to penetrate drugs across their biofilm barriers. The objective of this study was to investigate the antibacterial susceptibility of antibiotic-resistant bacteria and contact lens barrenness. Nilavembu Choornam–Gold [...] Read more.
Antibiotic-resistant bacterial colonies mitigate rapid biofilm formation and have complex cell wall fabrications, making it challenging to penetrate drugs across their biofilm barriers. The objective of this study was to investigate the antibacterial susceptibility of antibiotic-resistant bacteria and contact lens barrenness. Nilavembu Choornam–Gold Nanoparticles (NC–GNPs) were synthesized using NC polyherbal extract and characterized by UV-visible spectrophotometer, SEM-EDX, XRD, Zeta sizer, FTIR, and TEM analysis. Contact lenses with overnight cultures of antibiotic-resistant bacteria K. pneumoniae and S. aureus showed significant differences in growth, biofilm formation, and infection pathogenicity. The NC–GNPs were observed in terms of size (average size is 57.6 nm) and surface chemistry. A zone of inhibition was calculated for K. pneumoniae 18.8 ± 1.06, S. aureus 23.6 ± 1.15, P. aeruginosa 24.16 ± 0.87, and E. faecalis 24.5 ± 1.54 mm at 24 h of NC–GNPs alone treatment. In electron microscopy studies, NC–GNP-treated groups showed nuclear shrinkage, nuclear disintegration, degeneration of cell walls, and inhibited chromosomal division. In contrast, normal bacterial colonies had a higher number of cell divisions and routinely migrated toward cell multiplications. NC–GNPs exhibited antibacterial efficacy against antibiotic-resistant bacteria when compared to NC extract alone. We suggest that NC–GNPs are highly valuable to the population of hospitalized patients and other people to reduce the primary complications of contact lens contamination-oriented microbial infection and the therapeutic efficiency of antibiotic-resistant bacterial pathogenicity. Full article
(This article belongs to the Special Issue Nanomedicine Advances in the Treatment of Chronic Inflammation)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop